Pharmafile Logo
Pharmafocus logo
Advanced Search
hannah_pender

Living with a rare chromosome disorder

April 11, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Inv Dup Del 8p, feature, patient experience, pharma

Rebecca Pender’s daughter Hannah lives with the ultra-rare condition Inv Dup Del 8p, a genetic arrangement that affects just 80 …

Feature
1468995876_rb-centre-for-scientific-excellence

Reckitt Benckiser to unveil £105 R&D site in Hull by end of June

April 11, 2019
Manufacturing and Production Hull, R&D, Reckitt Benckiser, UK, pharma

Reckitt Benckiser (RB) has announced that its £105 million research and development facility in the UK city of Hull – …

News

Researchers use CRISPR to reveal gene targets in 30 types of cancer

April 11, 2019
Research and Development Cancer, crispr, drug development, genes, genetics, oncology

Researchers at the Wellcome Sanger Institute and Open Targets have been able to identify thousands of genes which play a …

News
novartis_window

Novartis’ Kisqali combo rejected by NICE for advanced breast cancer

April 11, 2019
Sales and Marketing Kisqali, NHS, NICE, Novartis, pharma

Novartis’ Kisqali (ribociclib) has been rejected for use on the NHS by NICE for the treatment of advanced breast cancer, …

News
gilead-sciences

Gilead to lay off one fifth of sales force

April 11, 2019
Sales and Marketing Gilead, Jobs, Letairis, Ranexa, redundancy, sales

Gilead Sciences is preparing to lay off around a fifth of its salesforce in anticipation for the expiry of patents …

News
fdaoutsideweb

FDA green lights Amgen and UCB’s Evenity in postmenopausal osteoporosis patients

April 10, 2019
Research and Development, Sales and Marketing Amgen, Evenity, FDA, UCB Pharma, osteoporosis, pharma

The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at …

News
suboxone_sl_tabs

Indivior shares fall by 70% after allegations of fraud

April 10, 2019
Research and Development Virginia, indivior, opioid crisis, opioids, suboxone

Shares in London-listed Indivior plummeted this morning after US Federal prosecutors said the British drugmaker had deceived doctors as to …

News
lynparza

Europe approves Lynparza in HER2-, gBRCAm advanced breast cancer

April 10, 2019
Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, breast cancer, lynparza, pharma

Lynparza (olparib), the poly ADP ribose polymerase (PARP) inhibitor developed by AstraZeneca and MSD, has been awarded marketing approval by …

News
brooklyn-bridge-768668_960_720

New Yorkers must be vaccinated or face a fine

April 10, 2019
Research and Development Brooklyn, New York, infectious diseases, measles, public health, vaccines

A public health emergency has been declared in New York following an outbreak of measles. Residents of certain postcodes in …

News
senatefloor

Pharmacy Benefit Manager (PBM) execs testify before US Senate

April 10, 2019
Research and Development PBMs, Rebates, Senate, US, pharma, senator, sfc

Executives representing pharmacy benefit managers (PBMs) appeared before the US Senate Finance Committee on Tuesday as they testified on the …

News
shutterstock_57369385

Epilepsy Society calls for review of UK supply chain following “steep rise” in access issues

April 9, 2019
Manufacturing and Production, Sales and Marketing Epilepsy Society, UK, brexit, epilepsy, market access, pharma

The Epilepsy Society has drawn attention to the “steep rise” in UK patients who are encountering difficulty in accessing seizure …

News
credit_rich_s

United Therapeutics terminates oral pulmonary arterial hypertension drug following Phase 3 failure

April 9, 2019
Manufacturing and Production, Research and Development Tyvaso, United Therapeutics, pharma, pulmonary arterial hypertension

United Therapeutics has revealed in a short announcement that, because its pulmonary arterial hypertension (PAH) therapy failed to meet its …

News
shutterstock_349943306

FDA refuses to review Zogenix’s Fintepla in Dravet syndrome, shares tumble 30%

April 9, 2019
Manufacturing and Production, Sales and Marketing Dravet Syndrome, FDA, Fintepla, Zogenix

California-based biopharma firm Zogenix has been left frustrated after it received a correspondence from the FDA noting its refusal to …

News

ViiV Healthcares scores first twin-drug FDA approval for untreated HIV-1

April 9, 2019
Manufacturing and Production, Research and Development GSK, HIV, ViiV Healthcare, pharma

ViiV Healthcare, the pharmaceutical firm owned by Shionogi, Pfizer and predominantly GSK, has announced its two-drug HIV regimen Dovato (dolutegravir …

News

Eisai and MSD’s Lenvima recommended for NHS Scotland in advanced or unresectable liver cancer

April 8, 2019
Manufacturing and Production, Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, liver cancer, pharma

Patients in Scotland with with advanced or unresectable hepatocellular carcinoma (HCC) will now be able to access Eisai and MSD’s …

News
simon-sturge-kymab-tile

Kymab announces Merck exec Simon Sturge as new CEO

April 8, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, appointment, kymab, pharma

UK-based biotech Kymab has identified Merck KGaA executive Simon Sturge as its new Chief Executive Officer, taking over the reins …

Appointment
real_world

Protecting public health: Is real-world evidence the key?

April 8, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing feature, pharma, real world data, real world evidence, real-world data, real-world evidence

In often tough regulatory climates and with threats to public health are growing in sceptical corners of society, the need …

Feature

NICE turns down Astellas’ Xtandi in prostate cancer

April 8, 2019
Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer

Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for …

News
shutterstock_159488225

Alnylam and Sanofi close research phase of 2014’s $700m RNAi rare disease partnership

April 8, 2019
Research and Development, Sales and Marketing Alnylam, Genzyme, Sanofi, pharma, rare disease

Alnylam and Sanofi have announced their intention to bring to an end the research and option phase of a $700 …

News
x_ray_health_arm_doctors_medicine_bone_hospital_medical_insurance-480473

Osteoporisis risk in over half of European women over 70, three-quarters not treated, Amgen study finds

April 8, 2019
Research and Development, Sales and Marketing Amgen, Europe, UK, bones, osteoporosis, pharma, real world data, real-world data

A new study from Amgen analysing real-world data has revealed that more than half of European women over 70 years …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026